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FULL MANUSCRIPT
Soluble Mediators in Platelet Concentrates
Modulate Dendritic Cell Inflammatory Responses
in an Experimental Model of Transfusion
Alexis J. Perros,1,2 Anne-Marie Christensen,1,2 Robert L. Flower,1,2 and Melinda M. Dean1,2
The transfusion of platelet concentrates (PCs) is widely used to treat thrombocytopenia and severe trauma. Ex
vivo storage of PCs is associated with a storage lesion characterized by partial platelet activation and the release
of soluble mediators, such as soluble CD40 ligand (sCD40L), RANTES, and interleukin (IL)-8. An in vitro
whole blood culture transfusion model was employed to assess whether mediators present in PC supernatants
(PC-SNs) modulated dendritic cell (DC)-specific inflammatory responses (intracellular staining) and the overall
inflammatory response (cytometric bead array). Lipopolysaccharide (LPS) was included in parallel cultures to
model the impact of PC-SNs on cell responses following toll-like receptor-mediated pathogen recognition. The
impact of both the PC dose (10%, 25%) and ex vivo storage period was investigated [day 2 (D2), day 5 (D5),
day 7 (D7)]. PC-SNs alone had minimal impact on DC-specific inflammatory responses and the overall
inflammatory response. However, in the presence of LPS, exposure to PC-SNs resulted in a significant dose-
associated suppression of the production of DC IL-12, IL-6, IL-1a, tumor necrosis factor-a (TNF-a), and
macrophage inflammatory protein (MIP)-1b and storage-associated suppression of the production of DC IL-10,
TNF-a, and IL-8. For the overall inflammatory response, IL-6, TNF-a, MIP-1a, MIP-1b, and inflammatory
protein (IP)-10 were significantly suppressed and IL-8, IL-10, and IL-1b significantly increased following
exposure to PC-SNs in the presence of LPS. These data suggest that soluble mediators present in PCs
significantly suppress DC function and modulate the overall inflammatory response, particularly in the
presence of an infectious stimulus. Given the central role of DCs in the initiation and regulation of the
immune response, these results suggest that modulation of the DC inflammatory profile is a probable
mechanism contributing to transfusion-related complications.
Introduction
Platelets (PLTs) are key contributors to coagulationand wound healing, as well as providing a significant
contribution to inflammation and innate immune responses
( Jurk and Kehrel 2005). Transfusion of platelet concen-
trates (PCs) is standard in the treatment of thrombocyto-
penia and severe trauma (Hunt 1998; Sahler and others
2012). In addition, the transfusion of PCs is used prophy-
lactically to maintain hemostasis in patients undergoing
ablative chemotherapy before bone marrow transplantation
(Hunt 1998; Sahler and others 2012).
While it is clear that PC transfusions are an effective
therapy, they have the potential to modulate the immune
system, contributing to poor clinical outcomes, including
increased length of stay in intensive care, prolonged venti-
lation, infection, mortality, and severe trauma (Heddle and
others 1993; Spiess and others 2004; Aslam and others
2008; Kiefel 2008; Bilgin and others 2011; Refaai and
others 2011; Sahler and others 2011).
Poorer clinical outcomes in patients post-transfusion,
associated with modulation of the recipient’s inflammatory
profile and immune response, are referred to as transfusion-
related immunomodulation (TRIM) (Aslam and others
2008; Bilgin and Brand 2008). The mechanisms underlying
TRIM as a result of PC transfusion remain largely un-
known. A few mechanisms have been proposed, including
the presence of residual leukocytes in PCs (Slichter and
others 2005) and the release of major histocompatibility
complex (MHC) class I molecules associated with PC
storage (Ghio and others 1999). Despite these hypotheses,
the underlying mechanisms, key cells, and mediators of
adverse transfusion complications post-PC transfusion re-
main largely undefined.
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PCs are routinely stored for up to 7 days before transfu-
sion, although country-specific guidelines exist [eg, 7-day
expiry in Ireland, Denmark, the Netherlands, and the United
Kingdom (Korte 2011; Sto¨rmer and Vollmer 2014) and
5-day expiry in Australia (National Health and Medical
Research Council and the Australasian Society of Blood
Transfusion 2002)]. The 7-day expiry was introduced in
some countries following the introduction of bacterial
screening for all PLT products and extensive quality testing
comparing day 5 (D5) and day 7 (D7) PCs. While Australia
has introduced bacterial screening, the current shelf life
remains at 5 days.
Significant biochemical and biological changes occur
during ex vivo storage of PCs (Sparrow 2010; Spiess 2010;
Sahler and others 2011). During storage, PLTs become
partially activated, lose metabolic function, and PLT matrix
adhesion properties are altered (Boomgaard and others
1994; Rosenfeld and others 1995; Seghatchian 2006; Shri-
vastava 2009; Sahler and others 2011). In addition, the re-
lease of biological mediators, including histamine (Konca
and others 2006), soluble CD40 ligand (sCD40L) (Kaufman
and others 2007), P-selectin, RANTES, PLT factor-4 (PF4),
transforming growth factor-b (TGF-b), and interleukin (IL)-
8 (Apelseth and others 2006; Sahler and others 2011), have
widely been reported to increase in the PC during routine
storage.
Despite these biochemical and biological changes, the
relationship between blood product storage before transfu-
sion and poorer clinical outcomes in patients remains con-
troversial (Boehlen and Clemetson 2001; Karkouti and
others 2006; Koch and others 2008; Sparrow 2010; Spiess
2010; Sahler and others 2011). The accumulation of
sCD40L, in particular, could have a detrimental impact on
clinical outcomes by inducing inflammation, impacting
other mediators downstream, inducing cytokine and che-
mokine release and adhesion molecule surface expression,
and driving dendritic cell (DC) maturation (Martinson and
others 2004; Kaufman and others 2007; Hamzeh-Cognasse
and others 2008; Sahler and others 2012).
The presence of biological mediators in PCs may affect
the function of important immune cells such as DCs. DCs
play a central role at the interface of the innate and adaptive
immune response as they are the only antigen-presenting
cells that can present antigens to naı¨ve T cells (Lee and
Iwasaki 2007). Therefore, dysfunction in the DC, a key
immunoregulatory cell, may contribute to adverse compli-
cations of transfusion contributing to TRIM.
In humans, there are 2 main subtypes of blood DCs, the
myeloid DCs; CD11c+ with a monocytoid appearance,
which produce tumor necrosis factor-a (TNF-a), and plas-
macytoid DCs; CD11c-, which are morphologically similar
to plasma cells and produce interferons, in particular inter-
feron-a (IFN-a) (Reid and others 1992; Robinson and others
1999; Adams and others 2005). While these cells have a
similar capacity to stimulate an immune response (Ban-
chereau and others 2000), they differ in terms of tissue
distribution, cytokine production, and growth requirements
(Banchereau and others 2000; Adams and others 2005).
DCs express a number of pattern recognition receptors
(PRRs) that interact with pathogen-associated molecular
patterns or damage-associated molecular patterns. PRRs
expressed by DCs include C-type lectins, mannose recep-
tors, and toll-like receptors (TLRs) (Lee and Iwasaki 2007).
Upon activation of PRRs and receptor/ligand binding, DCs
undergo differentiation and antigens are processed for pre-
sentation on MHC class I and/or MHC class II molecules.
Together with changes in expression of adhesion mole-
cules and TLRs, antigen presentation mediates DC migra-
tion from the tissue to the draining lymph node through the
lymphatic system (Sallusto and others 1998; Lee and Iwa-
saki 2007). During this process, costimulatory molecules
and cytokines (such as IFN-a or TNF-a) are released, as-
sisting in the maturation process and activation of naı¨ve T
cells, eosinophils, macrophages, and natural killer (NK)
cells (Banchereau and others 2000; Lee and Iwasaki 2007).
Despite a clear understanding of the basic functions of DCs,
little is known about transfusion-associated modulation of
these key immunological processes.
Given the central role of DCs in the initiation and regu-
lation of the immune response, the potential for dysfunction
in these cells needs to be considered as a potential mecha-
nism contributing to transfusion-related complications.
Using in vitro models, transfusion-mediated modulation of
DC costimulatory molecules and inflammatory responses
has recently been described following exposure to packed
red blood cells (PRBCs) (Dean and others 2013). In-
flammatory cytokines, IL-6, TNF-a, IL-1a, chemokine
macrophage inflammatory protein (MIP)-1a, and activation
molecule CD83, were proposed as potential biomarkers
associated with PRBC transfusion-related modulation of DC
function (Dean and others 2013).
Based on similar panels and established assays, this study
aimed to investigate transfusion-associated changes in the
DC inflammatory profile following exposure to PCs. Given
that it is well accepted that PLTs modulate DC responses
(Mazzoni and others 2001; Martinson and others 2004;
Hamzeh-Cognasse and others 2008; Gudbrandsdottir and
others 2013; Hottz and others 2014), the soluble rather than
cellular component of PCs was investigated in this study.
Furthermore, this study was designed to provide insight into
the extent to which immunomodulation is affected by PC
dose and/or ex vivo storage period.
Materials and Methods
Platelet concentrates
Leukodepleted buffy coat-derived PCs (pooled from the
buffy coat of 4 whole blood donations) were obtained from
the Australian Red Cross Blood Service (Blood Service,
Brisbane). The PCs were prepared according to standard
Blood Service protocols based on the Council of Europe
Guidelines for the preparation and quality assurance of
blood components (Council of Europe 2008). PCs were
stored under routine conditions (20–24C with gentle agi-
tation) at 326mL (–14mL) at a concentration of 284· 109
PLTs per pool (–40· 109 PLTs per pool).
In Australia, PCs are routinely stored for up to 5 days
before transfusion, while a number of European countries,
including Denmark, Ireland, The Netherlands, and the
United Kingdom, routinely store PCs for up to 7 days before
transfusion. Therefore, we considered whether a 7-day ex-
piry would further impact on the immunomodulatory ca-
pacity of soluble mediators in PCs. Thus, following 2 (fresh,
n = 2), 5 (expiry, n= 2), or 7 (extended expiry, n = 3) days of
storage, PC supernatant (PC-SN) was aseptically collected
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following 2 subsequent centrifugation steps at 1,500 g for
15min and at 3,000 g for 10min. PC-SN was aliquoted and
stored at -80C until use in the in vitro assay.
Ethics
This study was approved by the Australian Red Cross
Blood Service Human Research Ethics Committee
(2012#05). Whole blood from consenting volunteers was
collected in ethylenediaminetetraacetic acid (EDTA)-antic-
oagulated tubes [Becton Dickinson (BD)] and utilized as the
recipient in the in vitro whole blood culture transfusion
model. EDTA-anticoagulated whole blood has been dem-
onstrated to be reliable and consistent for cytokine analysis
(Thavasu and others 1992; Flower and others 2000). PC-
SNs were used at a 10% replacement volume and a 25%
replacement volume approximating a 1 and 2–3 unit trans-
fusion, respectively.
In vitro whole blood culture transfusion model
PC-SNs [day 2 (D2), D5, or D7] and EDTA-anticoagulated
recipient whole blood from consenting volunteers were cul-
tured in RPMI 1640 media (containing 2mM L-glutamine;
Gibco by Life Technologies) in 24-well plates (Costar, Corn-
ing Life Sciences). The total volume was 1.5mL/well and a
10% and 25% replacement volume transfusion was set up
(10% replacement: 150mL PC-SN, 600mL RPMI, 750mL re-
cipient whole blood; 25% replacement: 375mL PC-SN, 375mL
RPMI, 750mL recipient whole blood). Lipopolysaccharide
(LPS, 1mg/mL; SigmaAldrich)was added to duplicatewells to
model an infectious complication. GolgiPlug (containing 0.1%
brefeldin A, 1mg/mL; BD Biosciences) was added after the
first hour to facilitate intracellular detection of inflammatory
markers.
For assessment of the overall inflammatory response,
the GolgiPlug was omitted. A no transfusion (no tx)
control (containing recipient blood and RPMI –LPS) was
run in parallel for each recipient to establish an individual
baseline for donor variation and facilitate analysis of
immunomodulation. Following a total of 6 h of incubation
(37C, 5% CO2), cells were then harvested and centri-
fuged (1,000 g, 2 min). The supernatant (SN) from wells
without the GolgiPlug was collected and stored at -80C
for assessment of the overall inflammatory response using
the cytometric bead array (CBA; see ‘‘Assessment of the
overall inflammatory response from the whole blood
culture transfusion model through CBA’’). The cells
harvested from wells containing the GolgiPlug were as-
sessed for DC-specific cytokine production. (see ‘‘As-
sessment of DC inflammatory response from the whole
blood culture transfusion model through intracellular
staining’’).
Data represent the following combinations (D2: 4 recip-
ients, each cocultured with SN derived from 2 independent
PCs stored for 2 days, total n = 8; D5: 4 recipients, each
cocultured with SN derived from 2 independent PCs stored
for 5 days, total n= 8; D7: 3 recipients, 2 recipients co-
cultured with SN derived from 2 independent PCs stored for
7 days and 1 recipient cocultured with SN derived from 3
independent PCs stored for 7 days, total n = 7). The same
recipients were used for no LPS and LPS data within each
time point.
Assessment of DC inflammatory response
from the whole blood culture transfusion
model through intracellular staining
For wells with the GolgiPlug included, harvested cells
were surface stained [room temperature (RT), 15min, dark]
with a panel of fluorescently labeled monoclonal antibodies
to identify DC populations as follows: lineage [CD3, CD19,
CD20, CD34, and CD56, all fluorescein isothiocyanate
(FITC) conjugated], CD45-peridinin chlorophyll (PerCP),
CD11c-allophycocyanin (APC), human leukocyte antigen
DR (HLA-DR)-violet 450 (V450), and CD14-violet 500
(V500) (all from BD Biosciences).
Following surface staining, erythrocytes were then lysed
(FACS Lyse, RT, 10min, dark; BD Biosciences) and leu-
kocytes permeabilized (FACS Perm, RT, 10min, dark; BD
Biosciences). Leukocytes were then stained with phycoer-
ythrin (PE)-conjugated anti-human IL-6, IL-8, IL-10, IL-12,
IL-1a, TNF-a, MIP-a, MIP-1b, monocyte chemoattractant
protein (MCP)-1, and inflammatory protein (IP)-10 (30min,
RT, dark, all BD Biosciences), washed with 3% fetal calf
serum (Gibco by Life Technologies)/phosphate-buffered
saline (PBS; Gibco by Life Technologies), and resuspended
in 1% paraformaldehyde (PFA; Sigma Aldrich)/PBS (Gibco
by Life Technologies) before analysis using flow cytometry.
DCs were identified on flow cytometry dot plots as line-
age- CD14- HLA-DR+ CD11c+ and median fluorescent
intensity (MFI) was determined for each inflammatory
marker. A ratio of MFI was then determined (sample MFI/
matched no tx control MFI) for each inflammatory marker.
Log2 of the ratio was then calculated equalizing the no tx
control to zero, which represents the baseline and takes into
account biological variation between different individual
responses. In this way, a -1 result indicates a 2-fold sup-
pression compared with the matched no tx control, and a + 1
result indicates a 2-fold increase.
Assessment of the overall inflammatory response
from the whole blood culture transfusion model
through CBA
CBA (BD Biosciences) was used to assess the inflamma-
tory response in the culture SNs from the in vitro whole
blood culture transfusion model (wells incubated without
GolgiPlug). For the purpose of this study, the overall immune
response refers to quantification of the panel of markers out-
lined below and represents the combined inflammatory re-
sponse for all the leukocyte populations as these are present in
the whole blood model. CBA is a multiplex flow cytometry-
based sandwich immunoassay that utilizes a plex of capture
beads each with a defined fluorescence and each coated with a
different specific capture antibody. The CBA was performed
according to the manufacturer’s specifications (BD Bio-
sciences).
Briefly, culture SN and capture beads were mixed (1 h,
RT, dark), and PE-labeled detection reagent was then added
(2 h, RT, dark). Capture beads were then washed with wash
buffer, centrifuged (200 g, 5min), and resuspended in wash
buffer before flow cytometric analysis. Unknowns were in-
terpolated from standard curves run in parallel. The target
panel consisted of IL-4, IL-6, IL-8, IL-10, IL-12, IL-1a, IL-
1b, TNF-a, MCP-1, MIP-1a, MIP-1b, IP-10, IFN-a, and
IFN-g (all BD Biosciences). Culture SNs were all tested in
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one batch with no freeze/thaw of samples to minimize
assay-to-assay variation. The limit of detection for this assay
was 10 pg/mL. For statistical analysis, the marker had to be
detected in at least 6 of 8 biological replicates (different
individual responses).
Flow cytometry
A 3-laser BD FACSCanto II flow cytometer (BD
Biosciences), along with FACS Diva, and FCAP Array
(both from BD Biosciences) were used for all flow cytom-
etry and associated analyses. For intracellular staining, a
minimum of 500 DC events were analyzed per treatment,
per inflammatory marker.
Statistical analyses
A repeated measure one-way analysis of variance (AN-
OVA) with Tukey’s post-test was used on paired data for
analysis of the MFI of inflammatory markers detected by
flow cytometry. A separate repeated measure one-way
ANOVA with Tukey’s post-test was performed on data
generated from each time point (D2, D5, D7) as different
recipients were used at each time point. A dose response
was considered present when the post hoc analyses indicated
a significant difference between a 10% and 25% dose, or,
between the no tx and 25% dose, but not between the no tx
and 10% dose.
To assess storage for DC-specific responses, the log2 MFI
was compared across D2, D5, and D7 for each dose (eg, D2
10%, D5 10%, D7 10%) using ANOVA with Tukey’s post-
test. To assess storage-associated modulation of the overall
immune response, the concentration (pg/mL) of each marker
was compared across D2, D5, and D7 within each dose
using ANOVA with Tukey’s post-test. A storage-associated
modulation was considered present when the post hoc ana-
lyses determined that there was a significant difference be-
tween D2, D5, and D7 for the 10% dose and/or the 25%
dose. For all statistical analyses, P values < 0.05 were con-
sidered significant. GraphPad Prism 5 (GraphPad software)
was used for all analyses and graphics.
Results
Assessment of the DC-specific inflammatory profile
in response to PC-SN in an in vitro whole blood
culture transfusion model
In the first instance, a panel of markers was used to assess
changes in DC inflammatory response following exposure to
SN derived from different buffy coat PCs that had been
stored for 2, 5, or 7 days. In the absence of LPS, there was
minimal modulation of the DC inflammatory profile. Of the
inflammatory markers tested, only production of IL-10
changed significantly, with suppression evident following
exposure to D5 PC-SN (ANOVA, P = 0.032, Fig. 1A). Dose-
associated suppression was also evident for DC IL-10 pro-
duction following exposure to D5 PC-SN ( post hoc 10% vs.
25%, P< 0.05, Fig. 1A).
IL-10 production was also suppressed when LPS was
included as a model of infection, with D2, D5, and D7 PC-
SNs significantly suppressing IL-10 production compared
with the matched LPS no tx control (ANOVA, P = 0.025
(D2), P = 0.007 (D5), P = 0.042 (D7), Fig. 1A). A dose-
associated response was evident at each of the time points
assessed, and, a storage-associated modulation of IL-10 was
also observed for both doses [Dose: post hoc LPS 10% vs.
LPS 25%, P< 0.05 (D2 and D5); post hoc no tx LPS vs. LPS
25%, P< 0.05 (D7). Storage: post hoc LPS 10% D2 vs. LPS
10% D7, P< 0.05; post hoc LPS 25% D2 vs. LPS 25% D7,
P < 0.05, Fig. 1A].
Significant modulation of a number of other key proin-
flammatory cytokines and chemokines was also observed
following exposure to PC-SNs in coculture with LPS. Sig-
nificant suppression of LPS-induced DC IL-8 production
was evident following exposure to D5 and D7 PC-SNs
[ANOVA, P = 0.034 (D5), P = 0.02 (D7), Fig. 1B] with a
significant dose-associated modulation at both D5 and D7
and storage-associated modulation evident for the 25% dose
[Dose: post hoc LPS 10% vs. LPS 25%, P < 0.05 (D5); post
hoc no tx LPS vs. LPS 25%, P < 0.05 (D7). Storage: post
hoc LPS 25%, P< 0.05 (D7), Fig. 1B]. Similar modulation
of IL-8 was also observed following exposure to D2 PC-SN,
but this did not reach significance.
For IL-6, IL-12, and MIP-1b, a significant dose-associ-
ated suppression of LPS-induced DC responses was evident
following exposure to D2, D5, and D7 PC-SNs [IL-6 AN-
OVA, P= 0.001 (D2), P= 0.027 (D5), P= 0.002 (D7); IL-12
ANOVA, P= 0.003 (D2), P = 0.013 (D5), P= 0.008 (D7);
MIP-1b ANOVA, P = 0.0001 (D2), P= 0.004 (D5),
P < 0.0001 (D7): for post hoc analysis, see Fig. 1C–E]. DC
production of MIP-a, MCP-1, and IP-10 was not signifi-
cantly modulated by D2, D5, or D7 PC-SNs in the presence
of LPS.
A clear dose-associated modulation of LPS-induced DC
production of IL-1a was observed following exposure to
D2, D5, and D7 PC-SNs [ANOVA, P= 0.022 (D2), P= 0.03
(D5), P = 0.030 (D7): for post hoc analysis, see Fig. 1F],
with a substantially different profile evident following ex-
posure to D5 and D7 PC-SNs (Fig. 1F). LPS-induced DC
production of TNF-a was significantly suppressed following
exposure to D7 PC-SN (ANOVA, P < 0.0001, Fig. 1G) with
both a significant dose- ( post hoc LPS 10% vs. LPS 25%,
P < 0.05) and storage-associated response ( post hoc LPS
25% D2 vs. LPS 25% D7, P < 0.05) observed. Suppression
of LPS-induced TNF-a production in DCs was evident
following exposure to D2 and D5 PC-SNs, but did not reach
significance.
These results suggest that soluble mediators present in
buffy coat-derived PCs significantly modulate the DC in-
flammatory profile, particularly when an infectious com-
plication was modeled. While both dose and storage
modulated the DC immune profile, the dose more than the
length of ex vivo storage affected DC function.
Assessment of the overall inflammatory response
to PC-SNs in an in vitro whole blood culture
transfusion model
In addition to the measurement of DC-specific responses,
the study design facilitated assessment of the overall in-
flammatory response in the culture SN from the in vitro
whole blood culture transfusion model. Using multiplex
CBA to quantify a panel of inflammatory markers, these
data represent the inflammatory response of the entire leu-
kocyte population present in the in vitro whole blood culture
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transfusion model. Using this approach, IL-4, IL-12, IL-1a,
IFN-a, and IFN-g were all below the limit of detection and
no further analysis could be undertaken (data not shown).
As observed for the DC-specific inflammatory response,
minimal PC-SN transfusion-associated modulation of the
overall inflammatory response was evident in the absence of
LPS. A significant induction in IP-10 production was ob-
served following exposure to PC-SN derived from PCs
stored for 2, 5, and 7 days, with a dose-associated response
evident following exposure to D2, D5, and D7 PC-SNs
[ANOVA, P< 0.0001 (D2), P= 0.016 (D5), P= 0.003 (D7),
post hoc no tx vs. 25%, P< 0.05 (D2, D5, and D7), Fig. 2A].
Significant suppression of IL-6 was observed following
exposure to D5 PC-SN (ANOVA, P = 0.015, post hoc no tx
LPS vs. LPS 25%, P< 0.05, Fig. 2B). A significant induction
was also observed for MCP-1 following exposure to PC-SN
derived from PCs stored for 7 days with a dose-associated
response evident following exposure to D7 PC-SN (ANO-
VA, P= 0.025, post hoc no tx vs. 25%, P < 0.05, Fig. 2C).
In the presence of LPS as a model of infection, significant
suppression of IP-10, IL-6, TNF-a, MIP-1a, and MIP-1b
production was evident [IP-10 ANOVA, P< 0.0001 (D2),
P< 0.0001 (D5), P= 0.001 (D7); IL-6 ANOVA, P < 0.0001
(D2), P< 0.0001 (D5), P < 0.0001 (D7); TNF-a ANOVA,
P= 0.003 (D2), P < 0.0001 (D5), P = 0.001 (D7); MIP-1a
ANOVA, P < 0.0001 (D2), P< 0.0001 (D5), P < 0.0001
(D7); MIP-1b ANOVA, P< 0.0001 (D2), P < 0.0001 (D5),
P< 0.0001 (D7); Fig. 2A, B, D–F]. For IL-6, TNF-a, MIP-
1a, and MIP-1b, neither the PC storage period nor dose
further impacted on the production of these inflammatory
markers.
FIG. 1. Assessment of the DC-specific inflammatory pro-
file following exposure to D2, D5, and D7 PC-SNs. Flow
cytometry was used to measure DC-specific inflammatory
markers in cell cultures of an in vitro whole blood culture
transfusion model following exposure to SN derived from
D2, D5, and D7 PCs (6 h culture, 5% CO2, 37C). Minimal
PC-SN-associated modulation of the DC inflammatory re-
sponse was evident in the absence of LPS, with only modu-
lation of the DC inflammatory response evident for IL-10 (A).
In the presence of LPS, significant modulation of the DC
inflammatory response was observed for IL-10 (A), IL-8 (B),
IL-6 (C), IL-12 (D), MIP-1b (E), IL-1a (F), and TNF-a (G)
following exposure to PC-SN. Dose rather than ex vivo
storage period predominantly had a more profound effect on
the inflammatory response. Open symbols indicate culture
without LPS, and the solid symbols indicate culture with LPS
(1mg/mL). Circle, square, and diamond symbols represent
D2, D5, and D7 data, respectively. Y axis indicates log2-fold
change, normalized to the matched no tx control, indicated by
the dotted line at zero. X axis indicates dose (10%, 25%) and
PC storage period (D2, n= 8; D5, n= 8; D7, n= 7). Bars
represent mean – standard error of the mean (SEM). AN-
OVA indicated by an asterisk: *P < 0.050, **P < 0.010,
***P < 0.001. Tukey’s post-test (dose): no tx versus 25%,
aP< 0.050, aaP< 0.010. Tukey’s post-test: 10% versus 25%,
bP< 0.050, bbP< 0.010, bbbP< 0.001. LTukey’s post-test
(storage). ANOVA, analysis of variance; D2, day 2; D5, day
5; D7, day 7; DC, dendritic cell; IL, interleukin; LPS, lipo-
polysaccharide; MIP, macrophage inflammatory protein; no
tx, no transfusion; PC, platelet concentrates; PC-SN, PC
supernatants; TNF-a, tumor necrosis factor-a.
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For IP-10, a dose-associated response was evident fol-
lowing exposure to D2, D5, and D7 PC-SNs [post hoc no tx
LPS vs. LPS 25%, P< 0.05 (D2, D5 and D7), Fig. 2A].
Exposure to PC-SNs and LPS resulted in induction of MCP-
1 [ANOVA, P = 0.014 (D2), P = 0.001 (D7)] and IL-8
[ANOVA, P < 0.0001 (D2, D5, D7)] (Fig. 2C, G) produc-
tion, particularly at the 25% dose. This pattern was seen
across the storage time points tested, suggesting that the PC-
SN dose was important for modulation of MCP-1 and espe-
cially IL-8 production (For post hoc analysis, see Fig. 2C).
For IL-10 and IL-1b, a variable dose response was observed
in the presence of LPS (Fig. 2H, I). IL-10 production was
significantly increased following exposure to D2, D5, and D7
PC-SNs, with a 10% dose inducing more IL-10 than the 25%
dose at D5 [ANOVA, P=0.036 (D2), P=0.001 (D5), P=0.002
(D7), post hoc LPS 10% vs. LPS 25%, P<0.05 (D5), Fig. 2H].
For IL-1b, the 10% dose reduced production and the 25% dose
induced production [ANOVA, P=0.001 (D2), P=0.002 (D5),
P=0.001 (D7), Fig. 2I]. These results demonstrate that soluble
mediators present in PCs mediate significant dysregulation of
the overall inflammatory response, particularly in the presence
of an infectious stimulus.
Discussion
The transfusion of PCs is standard for the management of
thrombocytopenia and severe trauma to maintain coagula-
tion and hemostasis (Hunt 1998; Sahler and others 2012).
Unfortunately, this form of treatment also has the potential
to contribute to the development of transfusion-associated
complications, including infection, multiple organ dys-
function syndrome, and mortality (Heddle and others 1993;
Spiess and others 2004; Aslam and others 2008; Kiefel
2008; Bilgin and others 2011; Refaai and others 2011;
Sahler and others 2011); yet, the underlying mechanisms of
TRIM associated with transfusion of PCs remain largely
unknown.
FIG. 2. Assessment of the overall inflammatory response to
D2, D5, and D7 PC-SNs. Cytometric bead array was used to
quantitate inflammatory markers in culture SNs from the
in vitro whole blood culture transfusion model following ex-
posure to PC-SN derived from D2, D5, and D7 PCs (6 h cul-
ture, 5% CO2, 37C). Minimal PC-SN-associated modulation
of the inflammatory response was evident in the absence of
LPS with significant modulation only observed for IP-10 (A)
and IL-6 (B). In the presence of LPS as a model of infection,
significant modulation of IP-10 (A), IL-6 (B), MCP-1 (C),
TNF-a (D), MIP-1a (E), MIP-1b (F), IL-8 (G), IL-10 (H), and
IL-1b (I) was evident following exposure to PC-SN. Im-
portantly, dose rather than storage period had a more profound
effect on the inflammatory response. The open symbols indi-
cate culture without LPS, and the solid symbols indicate cul-
ture with LPS (1mg/mL). Circle, square, and diamond
symbols represent D2, D5, and D7 data, respectively. Y axis
indicates pg/mL. X axis indicates dose (10%, 25%) and ex vivo
PC storage period (D2, n= 8; D5, n= 8; D7, n= 7). Bars rep-
resent mean–SEM. ANOVA indicated by an asterisk:
*P< 0.050, **P< 0.010, ***P< 0.001. Tukey’s post-test: no
tx versus 25%, aP< 0.050, aaP< 0.010, aaaP< 0.001. Tukey’s
post-test: 10% versus 25%, bP< 0.050, bbP< 0.010, bbbP<
0.001. LTukey’s post-test (storage). IP, inflammatory protein;
MCP, monocyte chemoattractant protein.
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Human immune responses are regulated by a broad range of
cytokines and chemokines, which target and regulate the
multitude of cellular responses (Borish and Steinke 2003). In
this study, the impact of PC-SNs on a panel of proin-
flammatory, regulatory/anti-inflammatory, and differentiation/
proliferation cytokines and a number of chemokines was
evaluated in an in vitrowhole blood culture transfusion model.
DCs were the focus of this study due to their central role at
the interface of the innate and the adaptive immune response,
and we hypothesized that the transfusion of PCs would
modulate DC cytokine and chemokine production, poten-
tially impacting on clinical outcomes due to deregulated
cytokine and chemokine signaling. Buffy coat-derived PC-
SNs were used in this study rather than apheresis PC-SN as
buffy coat-derived PCs represent the majority of PCs used in
transfusion practice. We assessed the potential for both dose
and ex vivo storage period of PCs to impact on DC function.
This is the first report showing that soluble factors present in
PCs modulate DC immune responses as well as the overall
inflammatory response in a dose-associated manner.
The immune profile of DCs was investigated by intracel-
lular staining of inflammatory markers following culture with
PC-SNs in an in vitro whole blood culture transfusion model.
The use of this model facilitates cell-to-cell interactions
without the need for cell isolation procedures involving
density gradients or magnetic-assisted cell separation. Using
this model, there was minimal modulation of the DC profile
following exposure to PC-SN in the absence of LPS.
In contrast, when LPS was added as a model of infection,
significant suppression of DC cytokine and chemokine
production was observed following culture with PC-SNs. A
dose-associated suppression of DC production of IL-10, IL-
8, IL-6, IL-12, and MIP-1b was evident. Both dose- and
storage-associated modulations of DC production of TNF-a
were evident. We are unable to directly compare these
findings with other literature as, to date, there have been no
previous reports of the modulation of the blood myeloid DC
inflammatory profile following exposure to PC-SNs, high-
lighting the uniqueness of this study.
Monocyte-derived DCs (MoDCs) are one of the closest
comparable models to blood myeloid DCs, and modulation
of the immune profile of MoDCs has, however, previously
been reported following exposure to PCs that contained both
the PLTs and soluble components of the blood product
(Kissel and others 2006; Hamzeh-Cognasse and others
2008; Cognasse and others 2009). In a model using cultured
MoDCs, a reduction in levels of IL-12 and TNF-a and an
increase in IL-10 production were observed in culture SNs
following exposure of LPS-activated MoDCs to both resting
and thrombin receptor-activating peptide-activated PLTs
(Kissel and others 2006).
These results, based on MoDCs, support the observations
of this study in a number of ways; first, the reduction in IL-
12 and TNF-a production is similar to that observed in the
current study, and second, PLTs become partially activated
during routine ex vivo storage, so the nonactivated and ac-
tivated PLTs used in the aforementioned MoDC model also
approximate changes that may be associated with fresh and
stored PCs (Kissel and others 2006). Another study inves-
tigated PLT-associated changes in the MoDC profile and
reported a significant increase in DC surface receptor ex-
pression of CD80, CD83, and CD86 and, using a transwell
approach, indicated that the DC profile of activation was
different, depending on direct cell-to-cell interaction versus
soluble factors (Hamzeh-Cognasse and others 2008).
In a recent study (Loh and others 2015), significant sup-
pression of LPS-induced IL-12 production from monocytes
cultured with PCs or PC-SNs was reported in a whole blood
culture model of transfusion similar to that utilized in this
study. Taken together with the dose-associated suppression
of IL-12 observed in this study, the suppression of IL-12 in
monocytes and in SNs of MoDC cultures in separate inde-
pendent studies suggests that administration of PCs has the
potential to significantly impact on the outcome of the im-
mune response due to a lack of IL-12 production required
for differentiation and proliferation of DCs, NK cells, and T
cells (Borish and Steinke 2003).
In addition to the investigation of DC-specific modula-
tion, the in vitro whole blood culture transfusion model was
also used to assess changes in the overall inflammatory re-
sponse following exposure to PC-SNs. The overall inflam-
matory response represents the combined inflammatory
response of multiple cell subsets found in circulation that
would interact in the context of transfusion. Overall, while
some variation was evident between PC-SNs derived from
PCs stored for 2, 5, or 7 days, largely the same inflammatory
mediators were modulated to similar levels regardless of the
ex vivo storage period.
In the absence of LPS, IP-10 production was consistently
increased at all time points investigated, with a dose re-
sponse evident following exposure to D2, D5, and D7 PC-
SNs. Another primarily monocyte-derived chemokine,
MCP-1, was also increased following exposure to PC-SNs,
with a significant induction observed following exposure to
D7 PC-SN. IP-10 and MCP-1 have not been reported to
increase during routine storage of buffy coat-derived PCs
(Muylle and others 1993; Stack and Snyder 1994; Ferrer and
others 2000; Wadhwa and others 2000; Cognasse and others
2006; Costa and others 2012; Tung and others 2012; Kaur
and others 2015), and these data suggest that monocyte-
driven chemotaxis may be induced following exposure to
soluble mediators in PC-SNs.
With coculture of PC-SNs with LPS, quite a different
profile of modulation of the overall response was observed.
While MCP-1 was increased following exposure to D2 and
D7 PC-SNs, IP-10 production was reduced, suggesting di-
vergent pathways of response to soluble mediators present
in PCs. In addition to IP-10, the overall production of IL-6,
TNF-a, MIP-1a, and MIP-1b was significantly reduced
following coculture of PC-SNs and LPS. Of note, IP-10 and
IL-6 production was severely perturbed at the 10% dose,
indicating that even a 1 unit PC transfusion can result in a
significant suppression of these mediators and a dose re-
sponse was not observed due to the profound suppression
observed at the lowest dose studied.
Like MCP-1, PC-SNs significantly enhanced IL-8 pro-
duction in the presence of LPS, with a very clear dose-
associated response evident, which was independent of the
storage period of the PC-SNs. IL-8 is produced by a broad
range of inflammatory cells, including neutrophils and
monocytes (Harada and others 1994), and these data suggest
that PC-SNs contain soluble mediators that target IL-8-
mediated pathways associated with cell recruitment.
In our study, modulation of the overall inflammatory re-
sponse was largely dose-associated, not storage associated.
In addition, we observed a heterogeneous response, with
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suppression of proinflammatory mediators (IL-6 and TNF-
a) and simultaneous suppression and activation of mediators
driving cell recruitment. Our data highlights the complex
nature of biological therapeutics where multiple cell re-
ceptors and pathways can be engaged simultaneously and
the output is the result of balance of multiple factors.
While there has not been another in vitro study as com-
prehensive as this, these data are in line with some previous
observations. A study using an in vitro whole blood culture
transfusion model observed a significant reduction in LPS-
stimulated TNF-a and significant induction of IL-10 pro-
duction in the SN of 24-h cell cultures following incubation
with PCs (Schneider and others 2009). These findings differ
from our study as IL-10 production was found to be reduced
following exposure to PC-SNs. These conflicting outcomes
for IL-10 may be due to the different cell culture periods
(12/24 vs. 6 h) employed in the 2 in vitro models.
PCs are complex biological components, thus it is likely
that multiple mechanisms are involved in driving the im-
munomodulation detected in this study. While this study
has not specifically analyzed the biological mediators in the
PC-SN, the PLT storage lesion has previously been well
characterized. Ex vivo storage of PCs is associated with sig-
nificant increases in levels of histamine (Konca and others
2006), sCD40L (Kaufman and others 2007), P-selectin,
RANTES, PF4, TGF-b, and IL-8 (Slichter and others
2005; Sahler and others 2011).
Histamine has been reported to regulate the expression
and secretion of cytokines and chemokines during LPS-
driven maturation of DCs by downregulating IL-12, IL-6, IP-
10, MIP-3a, IL-18, and RANTES, while increasing levels of
IL-8 and IL-10 (Mazzoni and others 2001). Further study
into the specific role of histamine in PC-associated sup-
pression of immune responses would be warranted.
sCD40L is abundant in PCs and has the potential to in-
duce an inflammatory response and it has been reported to
drive DC activation and maturation following stimulation
with activated PLTs (Martinson and others 2004; Blumberg
and others 2006; Hamzeh-Cognasse and others 2008). The
accumulation of sCD40L, in particular, may have a detri-
mental impact on DC function by inducing inflammation,
impacting downstream mediators, inducing cytokine and
chemokine release (eg, MCP-1), inducing adhesion mole-
cule surface expression, and driving DC maturation (Mar-
tinson and others 2004; Sahler and others 2012).
PF4, stored in PLT alpha granules, is released during
routine ex vivo storage and has been reported to mediate a
reduction in IL-12 and TNF-a production from LPS-stimu-
lated MoDCs. Further experiments utilizing blocking studies
or selective filtration approaches of these known DC modu-
lators may be useful to define more specific mechanisms.
Proinflammatory cytokines, such as IL-6, IL-1a, and
TNF-a, promote the activation of the immune response,
leading to inflammation (Borish and Steinke 2003). These
responses are moderated by anti-inflammatory or regulatory
cytokines such as IL-10, which inhibit the production of
inflammatory mediators produced by key immune regula-
tors, such as T cells, B cells, and monocytes (Borish and
Steinke 2003). IL-12 is a key differentiation/proliferation
cytokine mainly produced by monocytes, macrophages, and
DCs. It is a key cytokine that is essential for differentiation,
cytotoxicity, cytokine production of NK cells, and prolif-
eration of T-helper and cytotoxic lymphocytes and plays a
key counter-regulatory role in an allergic inflammatory re-
sponse (Borish and Steinke 2003).
Chemokines are key mediators required for recruitment of
lymphocytes to the sites of inflammation (Borish and
Steinke 2003). Chemotactic signaling molecules, including
IL-8, MIP-1a, MIP-1b, MCP-1, and IP-10, are derived from
mononuclear phagocytes, T cells, neutrophils, and eosino-
phils and have the capacity to activate polymorphonuclear
cells and drive chemotaxis and cell recruitment to the sites
of inflammation (Borish and Steinke 2003). Given the sig-
nificant role these cytokines and chemokines play in the
immune response, modulation of these as a result of PC
transfusion and/or ex vivo storage can significantly impact
upon the patient, leading to poor outcomes. Such modula-
tion was clearly evident in this study, providing evidence of
the impact of PC transfusion on recipients’ immune profile.
PC-SN-associated modulation of inflammatory signals
(observed in this study) produced by DCs is likely to result
in significant perturbation of other detrimental downstream
immune processes. Monocytes act as myeloid precursors for
the differentiation of macrophages and DCs (Auffray and
others 2009; Hettinger and others 2013), and modulation of
key cytokines required for differentiation, as observed in
this study (eg, IL-12 and TNF-a) (Scheuerer and others
2000; Xia and Kao 2003), would significantly impact upon
the functions of these downstream mediators by impacting
the release of inflammatory mediators from other immune
cell subsets with potentially detrimental consequences to the
patient immune response post-transfusion.
DC-driven cytokine secretion (eg, TNF-a) is required as
an essential signal to activate T and B cells, naı¨ve T cells,
eosinophils, macrophages, and NK cells (Banchereau and
others 2000; Lee and Iwasaki 2007). Without activation of
these cell types as a result of PC-associated modulation of
cytokine and chemokine signaling, as observed in this study,
the recipient immune system would not be able to mount an
appropriate immune response, subsequently leading to in-
creased risk of infection, a common transfusion-associated
complication (Aslam and others 2008; Kiefel 2008).
Therefore, if DC function (eg, cytokine and chemokine
signaling) is compromised by soluble mediators in PCs, as
observed in this study, host immune responses would also be
compromised, leading to poor patient outcomes. In this
study, there was clear evidence of dose-associated sup-
pression of the DC-specific as well as the overall inflam-
matory responses. Therefore, it can be postulated that higher
doses of PC transfusions would be associated with more
significant modulation in the patient, increasing the likeli-
hood of transfusion-associated complications.
In summary, these novel findings demonstrate that soluble
mediators present in PCs modulate both the DC-specific and
overall inflammatory responses. These results suggest that
DC immunosuppression associated with PC transfusion may
contribute to poor patient outcomes, such as morbidity, and
increased rates of infection through a failure to induce an
appropriate adaptive immune response due to a lack of cy-
tokine and chemokine signaling. In addition, our data sug-
gest that in the absence of infectious complications, the
soluble mediators present in PCs have minimal impact on
the immune profile, but in patients with infectious compli-
cations, DC function may be significantly impaired fol-
lowing PC transfusion, particularly for patients receiving
multiple PC transfusions (>2–3 unit).
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